Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Yasuto Yoneshima; Isamu Okamoto; Tomotsugu Takano; Aimi Enokizu; Eiji Iwama; Taishi Harada; Koichi Takayama; Yoichi Nakanishi

doi:10.1016/j.lungcan.2015.03.012

Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Yasuto Yoneshima, Isamu Okamoto, Tomotsugu Takano, Aimi Enokizu, Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

Original language	English
Pages (from-to)	349-351
Number of pages	3
Journal	Lung Cancer
Volume	88
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2015.03.012
Publication status	Published - Jun 1 2015

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2015.03.012

Cite this

@article{0534a36ac3d84ace924d1d169ab5c0d0,

title = "Successful treatment with alectinib after crizotinib-induced esophageal ulceration",

abstract = "Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.",

author = "Yasuto Yoneshima and Isamu Okamoto and Tomotsugu Takano and Aimi Enokizu and Eiji Iwama and Taishi Harada and Koichi Takayama and Yoichi Nakanishi",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.lungcan.2015.03.012",

language = "English",

volume = "88",

pages = "349--351",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Successful treatment with alectinib after crizotinib-induced esophageal ulceration

AU - Yoneshima, Yasuto

AU - Okamoto, Isamu

AU - Takano, Tomotsugu

AU - Enokizu, Aimi

AU - Iwama, Eiji

AU - Harada, Taishi

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

AB - Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

UR - http://www.scopus.com/inward/record.url?scp=84929506043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929506043&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.03.012

DO - 10.1016/j.lungcan.2015.03.012

M3 - Article

C2 - 25837798

AN - SCOPUS:84929506043

SN - 0169-5002

VL - 88

SP - 349

EP - 351

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this